FDA Report on Postmarketing Requirements for Drug and Biologics Firms

Summary

The FDA is required to annually report on the status of postmarketing studies and clinical trials for approved drug and biologics products under the Food and Drug Administration Modernization Act of 1997, which mandates the agency to track the progress of these requirements and commitments.